

Emergent Biosolutions Inc.

Fact Sheet

E B S

LISTED

NYSE

EMERGENT BIOSOLUTIONS

QUICK REFERENCE

Emergent Biosolutions Inc.

NYSE: **EBS**

www.EMERGENTBIOSOLUTIONS.com

BUSINESS SUMMARY

At Emergent, our mission is to protect and enhance life. For 25 years, we've been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

EMERGENT BIOSERVICES (CDMO)

For biopharma innovators tackling the most serious health threats and rare diseases, Emergent has the scientific and regulatory compliance experience, development, and manufacturing resources, and efficient technology transfer capabilities to deliver the urgency, acuity, and scalability required to bring lifesaving and life enhancing products to market.

Whether you are in need of small volumes of material for clinical trials or large-scale manufacturing for commercialized products, Emergent can serve as a strategic and reliable CDMO partner to your drug product program.

PRODUCTS

- **ACAM2000**[®] (Smallpox (Vaccinia) Vaccine, Live)
- **ANTHRASIL**[®] [Anthrax Immune Globulin Intravenous (Human)]
- **BAT**[®] [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]
- **BioThrax**[®] (Anthrax Vaccine Adsorbed)
- **CYFENDUS**[®] (Anthrax Vaccine Adsorbed, Adjuvanted)
- **Ebanga**[™] (ansuvimab-zykl)
- **NARCAN**[®] Nasal Spray (naloxone HCl)
- **raxibacumab injection** A fully human monoclonal antibody
- **RSDL**[®] (Reactive Skin Decontamination Lotion Kit)
- **TEMBEXA**[®] (brincidofovir)
- **Trobigard**[®] Auto-injector (atropine sulfate, obidoxime chloride auto-injector)
- **VIGIV**[®] [Vaccinia Immune Globulin Intravenous (Human)]

CONTACT INFORMATION

Headquarters
300 Professional Drive
Gaithersburg, MD 20879

Investor Relations Contact
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

April 22, 2024 -- Emergent BioSolutions Inc. will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.

Conference Call Information

Participants can access the conference call live via webcast. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent's website.

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

- *As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country*
- *Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locations*
- *Approximately 22 million doses of NARCAN® Nasal Spray were distributed in the U.S. and Canada in 2023, and Emergent is committed to meeting any increase in demand driven by the evolving and worsening epidemic*
- *The recently announced 'White House Challenge to Save Lives from Overdose' is a nationwide call-to-action that includes increasing access to life-saving opioid overdose reversal medications, a program with direct alignment to Emergent's strategy and efforts since the launch of NARCAN® Nasal Spray in 2016*
- *Naloxone, the active ingredient in NARCAN® Nasal Spray, is a life-saving medication that can reverse an overdose from opioids, including heroin, fentanyl, and prescription opioid medications, when given in time*

March 28, 2024 -- Emergent BioSolutions Inc. remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported over 107,000 overdose deaths – a number that has risen almost every year and which has continued to break annual records.¹ This includes a rise in synthetic opioid overdoses mainly driven by fentanyl.¹ There is an inherent risk of potential overdose, wherever opioids are present, which has tragically become the leading cause of accidental death in the U.S.² These statistics only further underscore the need for multi-sectoral action to address and prevent opioid overdose deaths.

One year after Emergent obtained the **historic OTC U.S. FDA approval** in March 2023 and seven months since **retail launch** in August 2023, the availability of NARCAN® Nasal Spray in pharmacies, grocery stores and online retailers has helped more people gain access to this life-saving product. Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans. Since the OTC launch, NARCAN® Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites. Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.

In 2023, Emergent distributed approximately 22 million doses (~11 million two-dose cartons) in the U.S. and Canada through public interest organizations like state and harm reduction groups and retail locations.

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

March 25, 2024 -- Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, internet, company website and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Emergent Biosolutions Inc.

NYSE: EBS

[www.EMERGENTBIOSOLUTIONS.COM](http://www.emergentbiosolutions.com)

Barwicki Investor Relations • 30 Wall Street, 8 FL • New York, NY 10005

Deliver to: